구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | ALT-803 |
Overview Company | ImmunityBio, Inc. |
Overview Modality | CGT |
Overview Target | Acute Myeloid Leukemia |
Overview Indication | Melanoma |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | retroviral therapy (ART) were given 3 subcutaneous 6 mcg/kg doses of N-803 |
MoA Mechanism | and efficacy data of different vaccine platforms |
MoA Biomarker | PD-L1 expression |
PK/PD Species | Macaque, Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Macaque, Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer.. Cytokine induced memory-like natural killer (CIML NK) cells combined with an IL-15 super-agonist (N-803) are a novel modality to treat relapsed/refractory head and neck cancer. We report data from a phase I trial of haploidentical CIML NK cells combined with N-803 wi… |
Clinical Safety signal | First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer.. Cytokine induced memory-like natural killer (CIML NK) cells combined with an IL-15 super-agonist (N-803) are a novel modality to treat relapsed/refractory head and neck cancer. We report data from a phase I trial of haploidentical CIML NK cells combined with N-803 wi… |
Clinical Selected reported efficacy | ORR 33% |
Clinical Reported ORR | 80% |
Clinical Result source | ClinicalTrials.gov NCT02384954 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT02384954 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | ALT-803 |
Overview Company | ImmunityBio, Inc. |
Overview Modality | CGT |
Overview Target | Acute Myeloid Leukemia |
Overview Indication | Melanoma |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | retroviral therapy (ART) were given 3 subcutaneous 6 mcg/kg doses of N-803 |
MoA Mechanism | and efficacy data of different vaccine platforms |
MoA Biomarker | PD-L1 expression |
PK/PD Species | Macaque, Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Macaque, Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer.. Cytokine induced memory-like natural killer (CIML NK) cells combined with an IL-15 super-agonist (N-803) are a novel modality to treat relapsed/refractory head and neck cancer. We report data from a phase I trial of haploidentical CIML NK cells combined with N-803 wi… |
Clinical Safety signal | First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer.. Cytokine induced memory-like natural killer (CIML NK) cells combined with an IL-15 super-agonist (N-803) are a novel modality to treat relapsed/refractory head and neck cancer. We report data from a phase I trial of haploidentical CIML NK cells combined with N-803 wi… |
Clinical Selected reported efficacy | ORR 33% |
Clinical Reported ORR | 80% |
Clinical Result source | ClinicalTrials.gov NCT02384954 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT02384954 |
추천 비교
추천 비교